ArticleAnnals of medicine2025
Heterogeneity of the capsular warning syndrome; experiences of a single centre.
Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCapsular warning syndrome (CWS) is characterized by recurrent episodes of TIAs within a 24-hour, affecting at least two regions of the face, upper and/or lower extremities, and the absence of cortical symptoms.
backgroundCWS accounts for small percentage of TIAs. However, it is associated with a higher risk of stroke and permanent neurological deficits. In this article, we present the findings, treatment and prognosis of CWS.
methodsThis study reviewed the data of patients with cerebral small vessel disease. The clinical findings, the number and duration of CWS attacks, and treatments were noted. The NIHSS and the 3-month-mRS of the patients were evaluated to determine their prognosis.
resultsA total of 27 CWS cases were included, with an average age of 71.25 and 74.1% male. The most common lesion location was the internal capsule(51.8%), followed by the corona radiata. Dual antiplatelet therapy was the preference in 81.5% of patients. It was observed that the mean 3-month-mRS was 3.60 in the anticoagulation group and 0.90 in the antiplatelet group.
conclusionOur study highlights important information regarding lesion location, attack durations and treatment and shows that especially dual antiplatelet therapy is more effective in preventing permanent neurological deficits and CWS attacks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.